Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix

J. J. Kavanagh, D. Gershenson, L. Copeland, W. S. Roberts

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Twenty-four patients with recurrent or widespread adenocarcinoma of the cervix were treated with combination chemotherapy. The drugs used were 5-fluorouracil (5-FU) (500 to 800 mg/m2), doxorubicin (40 to 50 mg/m2), and cisplatin (50 to 60 mg/m2). The chemotherapy was administered as a 76-hour continuous infusion via a silastic central venous catheter and repeated every 28 days. The total response rate was 42% (25% complete and 17% partial). Median duration of response was 7 months. Areas of response were usually lung and lymph node metastases. Toxicity, mainly neutropenia, was acceptable. All patients relapsed. This combination chemotherapy results in a modest response rate for a malignancy about which there is little information regarding the treatment of disseminated disease. Future studies should determine the activity of this combination administered in a bolus fashion.

Original languageEnglish (US)
Pages (from-to)1621-1623
Number of pages3
JournalJournal of Clinical Oncology
Volume5
Issue number10
DOIs
StatePublished - 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix'. Together they form a unique fingerprint.

Cite this